| Migraine | |
|---|---|
| [^2] Neuroimaging placeholder [^3] | |
| ICD-10 | G43 |
| Classification | Primary headache disorder |
| Types | Migraine without aura, Migraine with aura, Chronic migraine, Hemiplegic migraine |
| Prevalence | ~1 billion people worldwide (12% of population) |
| Onset | Typically adolescence; peak prevalence 30-39 years |
| Gender Ratio | 3:1 female:male |
| Key Features | Recurrent headaches, photophobia, phonophobia, nausea |
| Pathophysiology | Trigeminovascular system, CGRP, cortical spreading depression |
Migraine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Migraine is a complex, recurrent primary headache disorder characterized by intense, throbbing headaches typically accompanied by nausea, photophobia (sensitivity to light),
and phonophobia (sensitivity to sound). It affects approximately 1 billion people worldwide, making it one of the most prevalent neurological conditions [1]. Migraine ranks as the second most
disabling disease globally according to the Global Burden of Disease studies, and is particularly impactful on working-age adults [2].
Migraine is classified into several subtypes, with migraine without aura (the most common form) and migraine with aura (characterized by transient neurological symptoms preceding or accompanying the headache) being the primary classifications. The disorder involves complex neurovascular mechanisms, including activation of the trigeminovascular system, release of calcitonin gene-related peptide (CGRP), and cortical spreading depression — a wave of neuronal depolarization that spreads across the cerebral cortex [3].
Recent research has increasingly highlighted potential relationships between migraine and neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease, and other neurodegenerative conditions. This connection has sparked significant research interest in understanding whether migraine might be a risk factor or early manifestation of these disorders [4].
Migraine demonstrates a striking age and gender distribution:
The most common form, characterized by recurrent headaches meeting specific criteria:
Characterized by transient focal neurological symptoms that precede or accompany the headache:
Defined as headache occurring on ≥15 days per month for >3 months, with migraine features on ≥8 days [7:1].
A rare variant with temporary motor weakness on one side of the body:
The trigeminovascular system is central to migraine pain generation [3:1]:
Cortical spreading depression (CSD) is a wave of neuronal depolarization that spreads across the cerebral cortex at 2-3 mm/minute [8]:
Multiple neurotransmitter systems are implicated in migraine pathogenesis:
Epidemiological and neuroimaging studies have revealed intriguing connections between migraine and AD [4:1]:
The relationship between migraine and PD has been increasingly recognized [12]:
Elevated levels of inflammatory biomarkers in migraineurs suggest chronic low-grade inflammation [13]:
Advanced neuroimaging reveals structural and functional brain changes in migraine [10:1]:
The study of Migraine has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications on migraine and its relationship to neurodegeneration.
Global, regional, and national burden of migraine and tension-type headache, 1990–2019 — The Lancet Neurology (2021). 1990. ↩︎ ↩︎
Global, regional, and national burden of diseases — The Lancet (2018). 2018. ↩︎
Migraine pathophysiology: Anatomy of the trigeminovascular pathway — Cephalalgia (2022). 2022. ↩︎ ↩︎
Migraine and Alzheimer's Disease: A systematic review and meta-analysis — Journal of Alzheimer's Disease (2023). 2023. ↩︎ ↩︎
Sex hormones and migraine: A narrative review — Cephalalgia (2023). 2023. ↩︎
Chronic migraine: Diagnosis and management — Current Neurology and Neuroscience Reports (2024). 2024. ↩︎ ↩︎
Cortical spreading depression: Mechanisms and clinical relevance — Brain (2023). 2023. ↩︎
CGRP and migraine: From pathophysiology to treatment — Cephalalgia (2024). 2024. ↩︎
Migraine and structural brain changes — Radiology (2022). 2022. ↩︎ ↩︎
Amyloid burden in migraine sufferers — Neurology (2023). 2023. ↩︎
Migraine and Parkinson's Disease — Movement Disorders (2024). 2024. ↩︎
Inflammatory biomarkers in migraine — Cephalalgia Reports (2024). 2024. ↩︎